ALLO
Price
$1.44
Change
+$0.06 (+4.35%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
300.91M
25 days until earnings call
PRME
Price
$1.41
Change
-$0.21 (-13.04%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
211.17M
34 days until earnings call
Ad is loading...

ALLO vs PRME

Header iconALLO vs PRME Comparison
Open Charts ALLO vs PRMEBanner chart's image
Allogene Therapeutics
Price$1.44
Change+$0.06 (+4.35%)
Volume$45.6K
Capitalization300.91M
Prime Medicine
Price$1.41
Change-$0.21 (-13.04%)
Volume$75.74K
Capitalization211.17M
ALLO vs PRME Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. PRME commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 05, 2025
Stock price -- (ALLO: $1.38 vs. PRME: $1.61)
Brand notoriety: ALLO and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 67% vs. PRME: 108%
Market capitalization -- ALLO: $300.91M vs. PRME: $211.17M
ALLO [@Biotechnology] is valued at $300.91M. PRME’s [@Biotechnology] market capitalization is $211.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 3 bullish, 6 bearish.
  • PRME’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, PRME is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -11.54% price change this week, while PRME (@Biotechnology) price change was -19.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.75%. For the same industry, the average monthly price growth was -16.58%, and the average quarterly price growth was -18.37%.

Reported Earning Dates

ALLO is expected to report earnings on Apr 30, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-10.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($301M) has a higher market cap than PRME($211M). ALLO YTD gains are higher at: -35.211 vs. PRME (-44.863). PRME has higher annual earnings (EBITDA): -196.34M vs. ALLO (-243.33M). ALLO has more cash in the bank: 292M vs. PRME (190M). PRME has less debt than ALLO: PRME (40.8M) vs ALLO (90.8M). PRME has higher revenues than ALLO: PRME (2.98M) vs ALLO (22K).
ALLOPRMEALLO / PRME
Capitalization301M211M143%
EBITDA-243.33M-196.34M124%
Gain YTD-35.211-44.86378%
P/E RatioN/AN/A-
Revenue22K2.98M1%
Total Cash292M190M154%
Total Debt90.8M40.8M223%
FUNDAMENTALS RATINGS
ALLO vs PRME: Fundamental Ratings
ALLO
PRME
OUTLOOK RATING
1..100
5914
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
9292
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (46) in the null industry is somewhat better than the same rating for ALLO (97) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than ALLO’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that ALLO’s stock grew similarly to PRME’s over the last 12 months.

ALLO's Price Growth Rating (92) in the Biotechnology industry is in the same range as PRME (92) in the null industry. This means that ALLO’s stock grew similarly to PRME’s over the last 12 months.

ALLO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that ALLO’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOPRME
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 5 days ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
80%
MACD
ODDS (%)
Bearish Trend 5 days ago
88%
Bullish Trend 5 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 17 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 26 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
89%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X83102.830000617.109400
+0.75%
Bitcoin cryptocurrency
SPY536.70-27.82
-4.93%
SPDR® S&P 500® ETF Trust
TSLA267.28-15.48
-5.47%
Tesla
GME21.10-1.59
-7.01%
GameStop Corp
AAPL203.19-20.70
-9.25%
Apple

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-4.17%
CRSP - ALLO
59%
Loosely correlated
-4.47%
FATE - ALLO
58%
Loosely correlated
-11.69%
NTLA - ALLO
56%
Loosely correlated
-5.62%
PRME - ALLO
51%
Loosely correlated
-10.06%
CRBU - ALLO
51%
Loosely correlated
-8.83%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-10.06%
CRSP - PRME
64%
Loosely correlated
-4.47%
NTLA - PRME
57%
Loosely correlated
-5.62%
RXRX - PRME
57%
Loosely correlated
-9.07%
BEAM - PRME
56%
Loosely correlated
-10.93%
ALLO - PRME
51%
Loosely correlated
-4.17%
More